These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Influence of CYP3A and CYP2C19 genetic polymorphisms on the pharmacokinetics of cilostazol in healthy subjects.
    Author: Yoo HD, Park SA, Cho HY, Lee YB.
    Journal: Clin Pharmacol Ther; 2009 Sep; 86(3):281-4. PubMed ID: 19516253.
    Abstract:
    The objective of this study was to investigate the influence of genetic polymorphisms in the CYP3A and CYP2C19 genes on cilostazol pharmacokinetics, with the drug being administered orally as a 50-mg single dose in healthy subjects. CYP2C19 genotypes in individuals with the CYP3A5*3/*3 genotype were associated with statistically significant differences (P < 0.05) in cilostazol pharmacokinetics parameters (apparent oral clearance (CL/F) and terminal half-life (t(1/2))). This indicates that CYP2C19 polymorphisms play an important role in the metabolism of cilostazol only in individuals with the CYP3A5*3/*3 genotype, which has low metabolic activity.
    [Abstract] [Full Text] [Related] [New Search]